Utah Medical Products Inc (UTMD) valuation
Utah Medical Products P/E ratio history
Utah Medical Products trades at 20.8 times its earnings over the last twelve months. At its last 10 fiscal year ends its P/E ranged from 15.5 (year to Dec 2024) to 35.6 (year to Dec 2017), with a median of 22.4.
| Fiscal year ended | Price | EPS | P/E |
|---|---|---|---|
| Dec 31, 2025 | $55.96 | $3.48 | 16.1 |
| Dec 31, 2024 | $61.47 | $3.96 | 15.5 |
| Dec 31, 2023 | $84.22 | $4.57 | 18.4 |
| Dec 31, 2022 | $100.53 | $4.51 | 22.3 |
| Dec 31, 2021 | $100.00 | $4.05 | 24.7 |
| Dec 31, 2020 | $84.30 | $2.94 | 28.7 |
| Dec 31, 2019 | $107.90 | $3.94 | 27.4 |
| Dec 31, 2018 | $83.08 | $4.95 | 16.8 |
| Dec 31, 2017 | $81.40 | $2.29 | 35.6 |
| Dec 31, 2016 | $72.75 | $3.22 | 22.6 |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Utah Medical Products valuation against its peers
| Company | Market value | P/E | Forward P/E | Price / sales |
|---|---|---|---|---|
| Utah Medical ProductsUTMD | $217M | 20.8 | — | 6.0 |
| Siga TechnologiesSIGA | $218M | — | 5.4 | 4.1 |
| Keros TherapeuticsKROS | $219M | — | — | 14.6 |
| Eledon PharmaceuticalsELDN | $214M | — | — | — |
| ElectromedELMD | $224M | 20.8 | 18.6 | 3.0 |
| Trisalus Lf Sc Cm ATLSI | $227M | — | — | 5.0 |
| Vanda PharmaceuticalsVNDA | $228M | — | — | 1.1 |
| Korro BioKRRO | $206M | — | — | 86.5 |
| Inhibikase TherapeuticsIKT | $205M | — | — | — |
| Peer median | 20.8 | 12.0 | 4.6 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: UTMD financials · UTMD returns
No forecast, no recommendation. This page describes Utah Medical Products Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.